Examkin

Soru

Zorluk: OrtaNeurocognitive Disorders

A 76-year-old man is evaluated in the clinic for progressive memory decline. Over the past 9 months, he has been increasingly forgetful, frequently misplacing household items, and recently became lost while driving home from his local grocery store. His son mentions that the patient's wife passed away 12 months ago; initially, the family attributed his forgetfulness to grief. The patient has a medical history of hypertension and bipolar I disorder, for which he has taken valproate for the past 25 years without any recent mood episodes. During the interview, the patient is cheerful, makes good eye contact, and attempts to joke away his memory lapses. When administered a cognitive assessment, he puts forth significant effort but scores 19/30, losing points on orientation, delayed recall, and intersecting pentagons. Which of the following is the most appropriate next step in management?

  1. Initiate donepezil therapyCevap
  2. B
    Initiate sertraline monotherapy
  3. C
    Initiate risperidone for schizophreniform disorder
  4. D
    Add amitriptyline to the current regimen
  5. E
    Discontinue valproate and begin observation

Cevap

Initiate donepezil therapy
The correct answer is initiating donepezil therapy. This patient presents with a classic progression of Alzheimer disease, characterized by an insidious onset of memory impairment (getting lost in familiar territory) and progressive cognitive decline over 9 months. A critical step in evaluating elderly patients with cognitive decline following a major life stressor (such as the loss of a spouse) is differentiating genuine major neurocognitive disorder from pseudodementia (major depressive disorder). Patients with genuine dementia often attempt to conceal their deficits (e.g., joking away memory lapses) and put forth significant effort on cognitive testing despite objectively failing. In contrast, patients with pseudodementia typically highlight their deficits, exert poor effort, and frequently answer questions with 'I don't know'. Because this patient has genuine dementia, initiating a cholinesterase inhibitor like donepezil is the most appropriate next step in management to help stabilize cognitive functioning.

Adım Adım Çözüm

1
Evaluate the clinical presentation to differentiate between genuine major neurocognitive disorder (dementia) and major depressive disorder (pseudodementia).
The patient's insidious 9-month decline, getting lost in familiar places, attempts to conceal deficits through joking, and poor cognitive performance despite high effort strongly indicate genuine dementia.
Bereavement can cause depressive symptoms (pseudodementia) that mimic dementia, but pseudodementia typically presents with poor effort (frequent 'I don't know' answers) and highlighting of cognitive deficits.
2
Determine the appropriate initial management for the confirmed diagnosis.
The patient requires symptomatic treatment for Alzheimer disease.
Cholinesterase inhibitors such as donepezil are first-line pharmacological treatments to temporarily improve cognition and function in major neurocognitive disorders.

Anahtar Kavram

Differentiating genuine major neurocognitive disorder from pseudodementia based on clinical presentation and cognitive testing effort.
Bu soruyu puanla

Konular

Neurocognitive Disorders

Bu konudan daha fazla soru